PHARMACY MARKET

Boston Scientific Announces partnership Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific | December 02, 2020

Boston Scientific Announces partnership Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business
Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections.

"This exchange will help the BTG Specialty Pharmaceuticals business upgrade its potential as a completely coordinated forte drugs stage," said Anthony Higham, president, BTG, Specialty Pharmaceuticals. "We accept our capacities and portfolio firmly supplement those of SERB, and we anticipate this next section as we keep on emphatically sway the lives of patients and the individuals who care for them."

The BTG Specialty Pharmaceuticals business creates, fabricates and markets life-sparing cures utilized in clinics and crisis care settings, including the clinically demonstrated and driving items CroFab®, DigiFab®, and Voraxaze®. The three establishments are required to produce roughly $210 million in income for the entire year 2020.

"In the wake of obtaining BTG in 2019 for around $3.7 billion net of money available, and following the end of this exchange, we will have stripped the two BTG non-clinical gadget parcels – Pharmaceutical Licensing sovereignties in the final quarter of 2019 and Specialty Pharmaceuticals declared today – for more than $1.0 billion in net continues," said Jeff Mirviss, chief VP and president, Peripheral Interventions, Boston Scientific. "We keep on being satisfied with the presentation of the center Interventional Medicines business, the essential driver of the BTG securing, which has conveyed solid development and is required to surpass our unique objective of $175 million in collaborations."

The arrangement incorporates the exchange of five offices and roughly 280 workers around the world. The exchange is relied upon to shut in the primary portion of 2021, subject to standard administrative endorsements and other shutting conditions.

Spotlight

The NHS could save £135 million a year through the widespread introduction of a pharmacist for every care home across the country according to a new report by the Royal Pharmaceutical Society (RPS), ‘The Right Medicine - Improving Care in Care Homes’ launched in February 2016.

Spotlight

The NHS could save £135 million a year through the widespread introduction of a pharmacist for every care home across the country according to a new report by the Royal Pharmaceutical Society (RPS), ‘The Right Medicine - Improving Care in Care Homes’ launched in February 2016.

Related News

PHARMACY MARKET

Treosulfan, a First-In-Class Conditioning Agent, is Licensed in Canada by Medexus Pharmaceuticals and Medac GmbH

Medexus Pharmaceuticals | July 13, 2021

Medexus Pharmaceuticals Inc. announced today that it has entered into a licensing deal with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be sold in Canada as Trecondyv and will be used in conjunction with fludarabine as part of a conditioning regime before allogeneic hematopoietic stem cell transplantation. Medexus will be in charge of selling and promoting the product, while Medac will manufacture and supply it. Medexus has been distributing treosulfan in Canada through the Special Access Program, and Health Canada recently approved Trecondyv for the treatment of adult patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes who are at increased risk for standard conditioning therapies, as well as pediatric patients older than one year with AML or MDS. About medac GmbH medac GmbH is a privately owned global pharmaceutical firm that is expanding its pharmaceutical and diagnostics businesses. Since its inception in Germany in 1970, medac has specialized in treating diseases related to oncology, hematology, urology, and auto-immune disorders. medac is dedicated to improving current therapeutic products and creating new ones to enhance patients' quality of life. In addition, medac has earned a reputation for developing novel medicines in less common indications. This dedication has resulted in a diverse range of pharmaceutical goods that positively impact the lives of patients. medac is constantly investing in product development and manufacturing and logistical capacities to fulfill the requirements of both patients and healthcare professionals. About Medexus Medexus is a market leader in novel rare disease treatment solutions, with a solid commercial platform in North America. We are building a highly distinctive business with a portfolio of innovative and high-value orphan and rare disease medicines that will support our growth for the next decade, based on a foundation of proven best-in-class medications. Through our key principles of Quality, Innovation, Customer Service, and Teamwork, the Company's goal is to offer the finest healthcare products to healthcare professionals and patients. Medexus Pharmaceuticals specializes in the treatment of auto-immune illness, hematological, and allergies. Rasuvo and Metoject, a unique methotrexate formulation (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor

Read More

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Moberg Pharma | November 06, 2020

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current convertible note agreement. By a separate press release, the Company has today announced its intention to distribute the BUPI project to the shareholders of Moberg Pharma through a Lex Asea distribution with a subsequent listing on Nasdaq First North Growth Market during the Q1 of 2021.

Read More

National Healthcareer Association (NHA) Launches Coalition for the Advancement of Pharmacy Technician Practice

Prnewswire | August 20, 2020

The National Healthcareer Association (NHA) has formed a unique, nationwide Pharmacy Technician Coalition. The coalition is focused solely on bringing pharmacy technician organizations, industry leaders, and associations together to advocate for and implement changes to expand the role of certified pharmacy technicians (CPhT), allowing them to help with needs during COVID-19. As pharmacies continue to provide more direct patient care services and are faced with increased workload during the pandemic, CPhTs have an opportunity to help with some of the pharmacists' duties, to be more efficient in delivering patient care.

Read More